<DOC>
	<DOC>NCT02389972</DOC>
	<brief_summary>The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.</brief_summary>
	<brief_title>Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study</brief_title>
	<detailed_description>Breakpoint cluster region (BCR) Abelson murine leukemia viral oncogene homolog 1 (c-ABL) Chronic myeloid leukemia (CML)</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Because this is a product registry study, it will include adult CML patients in any phase treated with dasatinib in China if they meet the following criteria: Willing and able to provide written informed consent ≥18 years of age Confirmed diagnosis of CML patients by attending physician Naive to dasatinib before enrollment in study treatment or have received &lt;3 months of dasatinib treatment Plan to or are receiving dasatinib therapy based on physician's clinical judgment Administered dasatinib after imatinibresistance or intolerance Patients participating in clinical trials for CML that explicitly prohibit recruitment in additional studies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>